Literature DB >> 31542295

Noradrenaline is crucial for the substantia nigra dopaminergic cell maintenance.

Sara Af Bjerkén1, Rasmus Stenmark Persson2, Anna Barkander3, Nina Karalija4, Noelia Pelegrina-Hidalgo3, Greg A Gerhardt5, Ana Virel3, Ingrid Strömberg3.   

Abstract

In Parkinson's disease, degeneration of substantia nigra dopaminergic neurons is accompanied by damage on other neuronal systems. A severe denervation is for example seen in the locus coerulean noradrenergic system. Little is known about the relation between noradrenergic and dopaminergic degeneration, and the effects of noradrenergic denervation on the function of the dopaminergic neurons of substantia nigra are not fully understood. In this study, N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) was injected in rats, whereafter behavior, striatal KCl-evoked dopamine and glutamate releases, and immunohistochemistry were monitored at 3 days, 3 months, and 6 months. Quantification of dopamine-beta-hydroxylase-immunoreactive nerve fiber density in the cortex revealed a tendency towards nerve fiber regeneration at 6 months. To sustain a stable noradrenergic denervation throughout the experimental timeline, the animals in the 6-month time point received an additional DSP4 injection (2 months after the first injection). Behavioral examinations utilizing rotarod revealed that DSP4 reduced the time spent on the rotarod at 3 but not at 6 months. KCl-evoked dopamine release was significantly increased at 3 days and 3 months, while the concentrations were normalized at 6 months. DSP4 treatment prolonged both time for onset and reuptake of dopamine release over time. The dopamine degeneration was confirmed by unbiased stereology, demonstrating significant loss of tyrosine hydroxylase-immunoreactive neurons in the substantia nigra. Furthermore, striatal glutamate release was decreased after DSP4. In regards of neuroinflammation, reactive microglia were found over the substantia nigra after DSP4 treatment. In conclusion, long-term noradrenergic denervation reduces the number of dopaminergic neurons in the substantia nigra and affects the functionality of the nigrostriatal system. Thus, locus coeruleus is important for maintenance of nigral dopaminergic neurons.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DSP4; Dopamine; In vivo amperometry; In vivo chronoamperometry; Noradrenaline; Parkinson's disease

Year:  2019        PMID: 31542295     DOI: 10.1016/j.neuint.2019.104551

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  6 in total

1.  Transcription Factors Phox2a/2b Upregulate Expression of Noradrenergic and Dopaminergic Phenotypes in Aged Rat Brains.

Authors:  Yan Fan; Fei Zeng; Russell W Brown; Jennifer B Price; Thomas C Jones; Meng-Yang Zhu
Journal:  Neurotox Res       Date:  2020-07-02       Impact factor: 3.911

Review 2.  Locus Coeruleus Modulates Neuroinflammation in Parkinsonism and Dementia.

Authors:  Filippo Sean Giorgi; Francesca Biagioni; Alessandro Galgani; Nicola Pavese; Gloria Lazzeri; Francesco Fornai
Journal:  Int J Mol Sci       Date:  2020-11-16       Impact factor: 5.923

Review 3.  The Noradrenergic System in Parkinson's Disease.

Authors:  Elena Paredes-Rodriguez; Sergio Vegas-Suarez; Teresa Morera-Herreras; Philippe De Deurwaerdere; Cristina Miguelez
Journal:  Front Pharmacol       Date:  2020-04-08       Impact factor: 5.810

Review 4.  Inflaming the Brain with Iron.

Authors:  Pamela J Urrutia; Daniel A Bórquez; Marco Tulio Núñez
Journal:  Antioxidants (Basel)       Date:  2021-01-06

Review 5.  Locus Coeruleus Malfunction Is Linked to Psychopathology in Prodromal Dementia With Lewy Bodies.

Authors:  Niels Hansen
Journal:  Front Aging Neurosci       Date:  2021-03-01       Impact factor: 5.750

Review 6.  Is there a Neurobiological Rationale for the Utility of the Iowa Gambling Task in Parkinson's Disease?

Authors:  Michael F Salvatore; Isabel Soto; Helene Alphonso; Rebecca Cunningham; Rachael James; Vicki A Nejtek
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.